Navigation Links
Spectros T-Stat Tissue Oximeter Clinical Studies Presented at PAS (Pediatric Academic Societies') Conference

PORTOLA VALLEY, Calif., May 19 /PRNewswire/ -- Spectros announced today that its T-Stat Tissue Oximeter was featured in two presentations at the Pediatric Academic Societies' (PAS) annual conference held in Baltimore, Maryland, May 2-5, 2009. The studies focused on clinical applications of the Spectros T-Stat monitor in the neonatal intensive care unit (NICU).

The first abstract was titled, "Visible Light Spectroscopy (VLS) for Detecting Alterations in Tissue Oxygenation with PRBC Transfusion in Very Low Birth Weight (VLBW) Neonates." The authors noted, "VLS is an easy to use and noninvasive method of assessment of tissue saturation in VLBW neonates with various severity of illness."

The second poster was titled, "Noninvasive Measurements of Plasma Bilirubin Levels Using Real-Time Visible Light Spectroscopy." The authors concluded visible light spectroscopy can be used as a method to measure real-time plasma bilirubin levels noninvasively. This compliments prior studies showing T-Stat can measure tissue or plasma met-hemoglobin and carboxy-hemoglobin.

"The utilization and acceptance of T-Stat has grown tremendously over the past 16 months as clinicians have increasingly recognized the need to monitor tissue perfusion in a reliable, reproducible, and quantitative way," commented Michael Fierro, Director of Clinical Studies. "We have additional studies in progress and will continue to demonstrate the efficacy of the T-Stat in reducing hospitalization costs and improving outcome in this high-risk population."

About Spectros

Spectros markets advanced molecular sensing and imaging devices that shed light on ischemia and cancer. The company's lead product, the T-Stat Tissue Oximeter, was the first medical device FDA-approved as sensitive to ischemia, an insufficient blood flow to tissue. T-Stat is the only commercially-available tissue oximeter that utilizes state-of-the-art visible light spectroscopy (VLS) technology. In clinical use, T-Stat is a real-time, absolute, noninvasive, and continuous tissue monitor that analyzes 260 wavelengths of light, far more than the 2-4 wavelengths used in other monitors for superior accuracy.

Spectros is also developing molecular diagnostic tools for breast and prostate cancer currently in phase I/II clinical trials supported by the National Cancer Institute. Spectros is a venture-supported private concern and markets its products in the U.S. and internationally.

(Note: Forward-looking statements are intended as a guide only, and do not constitute an offer for investment nor a guarantee of future events or returns. Certain Spectros applications described above have not been reviewed and approved by the FDA, and are for investigational use only. T-Stat is a registered trademark of the Spectros Corporation.)

SOURCE Spectros
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Fluorescent glass SRMs are new tool for spectroscopy
2. Spectros Corporation Reports 2007 Year-Over-Year Sales Rise 36%
3. Spectros Corporation Protects Its Cool White LED Spectroscopy Technology Against Alleged Infringement by Thermo Fisher Scientific
4. New Edition of Definitive Resource in Tissue Engineering Released Today
5. BioLife Solutions CryoStor(TM) Adopted by Tissue Regeneration Therapeutics for Preservation Protocol for New, Non-Embryonic Source of Stem Cells
6. TEI Biosciences Launches SurgiMend(TM) Collagen Matrix for Soft Tissue Reconstruction
7. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics Tissue of Origin Test Designed to Aid in Determination of a Tumors Origin
8. US Patent and Trademark Office Allows CRis Patent Application for Spectral Imaging of Deep Tissue
9. The closest look ever at native human tissue
10. Starion Achieves Worldwide Distribution of Proprietary Tissue Welding Technology
11. Osteotech Renews Tissue Recovery Agreement with the Euro Atlantic Transplant Alliance
Post Your Comments:
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Neurocrine Biosciences, ... Kevin Gorman , President and CEO of Neurocrine Biosciences, ... Healthcare Conference in New York . ... to visit the website approximately 5 minutes prior to ... A replay of the presentation will be available on ...
(Date:11/25/2015)... , November 25, 2015 ... Report is a professional and in-depth study on ...      (Logo: ) , ... the industry including definitions, classifications, applications and industry ... for the international markets including development trends, competitive ...
(Date:11/24/2015)... Nov. 24, 2015 Cepheid (NASDAQ: CPHD ... at the following conference, and invited investors to participate ...      Tuesday, December 1, 2015 at 11.00 a.m. ...      Tuesday, December 1, 2015 at 11.00 a.m. ... New York, NY      Tuesday, December ...
Breaking Biology Technology:
(Date:10/29/2015)... 29, 2015  The J. Craig Venter Institute (JCVI) ... Synthesis and Biosecurity: Lessons Learned and Options for the ... and Human Services guidance for synthetic biology providers has ... --> --> Synthetic biology ... potential to pose unique biosecurity threats. It now is ...
(Date:10/29/2015)... NXTD ) ("NXT-ID" or ... the growing mobile commerce market and creator of ... leading marketplace to discover and buy innovative technology ... on StackSocial for this holiday season.   ... a biometric authentication company focused on the growing ...
(Date:10/27/2015)... Calif. , Oct. 27, 2015 Synaptics Inc. ... solutions, today announced that Google has adopted the Synaptics ... touch controller solutions to power its newest flagship smartphones, ... by Huawei. --> ... like Google to provide strategic collaboration in the joint ...
Breaking Biology News(10 mins):